Former US FDA orphan drugs head joins National Organization for Rare Disorders
This article was originally published in SRA
Timothy R Coté has been appointed chief medical officer of the National Organization for Rare Disorders in the US, having served as director of the Food and Drug Administration's Office of Orphan Products Development between 2007 and May 2011. Dr Coté's new role will be to provide medical guidance in all areas – particularly advocacy and education – to promote fair, compassionate public policies; encourage the development of safe, effective treatments; and increase awareness of rare diseases and the needs of patients and their families.
You may also be interested in...
This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the European Union, and updates on EU marketing authorization changes recommended by the CHMP.
New medicines under evaluation at the European Medicines Agency.
The European Medicine Agency has recommended extending the therapeutic indication of a raft of drugs that are already authorized in the EU.